[Osteoporosis in RA: pathophysiology and treatment].
Ito
Yuji
Y
Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School.
Inoue
Daisuke
D
Matsumoto
Toshio
T
D001172:Arthritis, Rheumatoid / Q000150:complications*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002352:Carrier Proteins / Q000502:physiology; D016207:Cytokines / Q000502:physiology; D004035:Diet Therapy; D004164:Diphosphonates / Q000627:therapeutic use; D005081:Exercise Therapy; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology; D008562:Membrane Glycoproteins / Q000502:physiology; D010010:Osteoclasts; D010024:Osteoporosis / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy; D010281:Parathyroid Hormone / Q000627:therapeutic use; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B
D002352:Carrier Proteins; D016207:Cytokines; D004164:Diphosphonates; D005938:Glucocorticoids; D018836:Inflammation Mediators; D008562:Membrane Glycoproteins; D010281:Parathyroid Hormone; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; C505686:TNFRSF11A protein, human; C505688:TNFSF11 protein, human